Lloyd R. Kelland

发表

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

L. Kèlland, M. Valenti, B. Murrer, 1993, Cancer research.

Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.

L. Kèlland, B. Murrer, G. Abel, 1992, Cancer research.

Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.

C. O'Neill, L. Kèlland, B. Murrer, 1992, Cancer research.

Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.

L. Kèlland, J. Roberts, G. Abel, 1992, Cancer research.

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

S. Sidhar, L. Kelland, G. Abel, 1991, British Journal of Cancer.

Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.

P. Beale, L. Kèlland, S. Sharp, 2000, European journal of cancer.

BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.

N. Farrell, F. Zunino, R. Supino, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

P. Beale, L. Kèlland, P. Rogers, 2000, British Journal of Cancer.

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

C. O'Neill, B. Koberle, J. Masters, 1999, British Journal of Cancer.

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

T G Myers, T. Myers, P. Workman, 1999, Journal of the National Cancer Institute.

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

U. Banerji, M. Valenti, Lloyd R. Kelland, 2005, Clinical Cancer Research.

Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.

L. Kèlland, P. Rogers, S. Sharp, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

L. Kèlland, G. Abel, P. Mistry, 1992, British Journal of Cancer.

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

P. Workman, L. Kèlland, F. Raynaud, 2005, British Journal of Cancer.

Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.

M. Walton, L. Kèlland, J. Titley, 2000, Molecular pharmacology.